NAD+ injections: evidence, safety and costs

NAD+ injections are one of the most common items on longevity telehealth menus, usually sold for energy, focus and "cellular aging." The biology behind the pitch is real: NAD+ is a coenzyme at the center of energy metabolism ^[16]. The leap from that biology to a weekly shot is where the evidence runs out. A 2026 systematic review found no eligible intravenous or intramuscular NAD+ outcome trial for anti-aging or wellness through its search period ^[15].

NAD+ injections are compounded shots of a coenzyme your body already makes

Telehealth NAD+ injections are offered as compounded products. Verify the actual pharmacy and preparation; a seller’s label alone does not establish lawful compounding. There is no FDA-approved NAD+ drug, so no company has proved to FDA that a particular NAD+ shot is safe and effective for any use. A state-licensed pharmacy makes each lot from bulk NAD+ when a prescriber orders it.

That matters for two reasons. First, there is no FDA label, so there is no official list of uses, doses or side effects. Second, compounded drugs are not reviewed by FDA for quality before they ship. A 503A pharmacy compounds for individual prescriptions under state oversight; a 503B outsourcing facility makes larger lots and registers with FDA. The pharmacy type identifies the applicable framework, not whether a specific preparation satisfies every condition. Ingredient suitability, sterile procedures, testing and regulatory compliance all matter; a pharmacy’s name or registration alone does not guarantee a particular lot’s quality.

Why NAD+ is marketed for aging: the markers, not the outcomes

NAD+ is marketed for energy and aging because NAD+ levels decline with age and NAD-related markers are a busy area of aging research ^[15]. In rodents, raising NAD+ often improved metabolic and mitochondrial measures. That is the source of most of the claims you'll read.

Most human NAD research, though, doesn't use injected NAD+ at all. It uses oral precursors, chiefly NMN and NR, that the body converts to NAD+. The 2026 review found that these pills reliably raise NAD-related markers in blood, but their effects on function, metabolism and other healthspan outcomes were mixed and often null ^[15].

Two NMN trials show the pattern. In a 10-week placebo-controlled trial in postmenopausal women with prediabetes, NMN improved muscle insulin sensitivity; one author holds an NMN patent application ^[18]. In 60 older adults, 12 weeks of NMN raised blood NAD+ but did not change the main physical-function test, a stepping test; secondary walking-speed and sleep measures favored NMN, and three authors worked for a food company ^[19]. Neither study tells you what an NAD+ injection does. Our biomarker analysis explains why different formulations and outcomes need separate interpretation.

The size of the gap is worth seeing. The 2026 review searched studies from 2010 to October 2025 and kept 113: 80 in rodents and 33 in humans, 28 of them randomized ^[15]. No eligible human study in that review tested intravenous or intramuscular NAD+ against an anti-aging or wellness outcome. The only IV NAD+ study it found was the blood-level pilot described below, which it treated as background because it measured no clinical outcome.

Read the review's authorship too. Its first author owns a company that provides services to an aesthetics clinic, which the paper says does not offer NAD+ ^[15]. That disclosure doesn't change the count of trials, which anyone can check, but it belongs next to the finding.

A heart-failure trial improved its primary heart-pumping measure

The largest randomized trial of NAD+ given directly enrolled 180 adults with heart failure from ischemic cardiomyopathy. A 7-day IV course on top of standard care raised the heart's ejection fraction at one month, 45.4% against 42.4% on placebo ^[16].

The outcome patients feel was a different story. Major cardiac and cerebrovascular events over six months were 14.6% with NAD+ against 24.7% with placebo, a gap that was not statistically significant (p = 0.089) ^[16]. It was a single-center trial in people with a serious heart condition, not healthy adults looking for energy.

Why doesn't the heart result carry over to wellness shots? The patients had diagnosed heart failure, the NAD+ was given by IV in a hospital for one week, and the result that reached significance was a heart-scan number, not how people felt or how long they lived. Healthy adults injecting NAD+ at home for months are a different population, route and timescale, and no trial has studied them.

Nobody has shown that injected NAD+ raises NAD+ inside human tissue

A shot of NAD+ only helps if NAD+ gets where it is needed. The best data on that come from a 2019 pilot that ran a 6-hour IV drip of NAD+ and measured blood and urine. Plasma NAD+ did not change for the first two hours; the body cleared it as fast as it arrived ^[17]. NAD+ and a breakdown product showed up in urine by hour six.

That study measured blood, not muscle or brain, and two of its authors work for an NAD+ clinic and its research arm ^[17]. No published study has measured whether a subcutaneous NAD+ shot, the form telehealth providers ship, raises NAD+ inside human tissue. For a closer look at the IV version, see NAD+ IV therapy.

No FDA label means no FDA-reviewed list of side effects

NAD+ injections have no FDA label, so there is no FDA-reviewed list of side effects or warnings. A 2026 retrospective commercial-clinic report recorded infusion symptoms in all six NAD+ recipients; the comparison group received NR, without a saline placebo ^[9]. Symptoms resolved after the infusion, but this tiny, nonrandomized report cannot estimate risk in the general population. All authors were employed by the clinic company. Neither the heart-failure trial nor the infusion pilot was built to measure the safety of repeated home injections.

What FDA has published is a quality alert. In a notice last updated in October 2024, FDA said it was aware of compounders making intravenous products from food-grade NAD+, which carries a high risk of microbial and endotoxin contamination ^[10]. In October 2025 FDA classified one manufacturer's recall of NAD+ injection vials as Class I, its most serious category, for elevated endotoxin levels ^[11]. The recall doesn't tell you about any particular provider's product, which is why the pharmacy's name matters.

What you can check is the product itself. Ask which pharmacy compounds your NAD+, whether it is a 503A pharmacy or a 503B outsourcing facility, and how it tests each lot for sterility and strength. We go through the open safety questions in are NAD+ injections safe.

NADH and other versions on telehealth menus

You may see NADH as well as NAD+. NADH is the reduced form of the same coenzyme, and FDA lists it in Category 1 alongside NAD ^[12]. The form matters for what's in the vial, but it has its own older Parkinson’s disease literature. An open-label intravenous report in 34 patients described improvement, while a double-blind study with five NADH recipients and four controls found no statistically significant clinical improvement ^{[1] [2]}. Neither establishes wellness benefits from current NAD+ shots. If the label on your vial and the name on your plan don't match, ask the pharmacy which substance it compounded.

FDA status: a conditional interim policy, not approval

FDA lists "Nicotinamide Adenine Dinucleotide (NAD)" and the reduced form NADH in Category 1 of its 503A categories, last updated May 14, 2026 ^[12]. Category 1 means FDA is still evaluating the substance for its bulks list. In the meantime, FDA says it does not intend to act against licensed pharmacies that compound it under the interim policy's conditions ^[13].

A related salt, beta-nicotinamide adenine dinucleotide disodium salt trihydrate, sits in Category 3, nominated without enough support ^[12]. FDA revised the interim policy on January 7, 2025, so that substances nominated after that date no longer enter the categories at all; Category 1 entries stay put until FDA decides ^[14].

Evidence differs by route; wellness benefits remain unestablished

Telehealth providers sell NAD+ in more forms than the research covers. The injection is the most common, but nasal sprays, patches, face creams and oral tablets or liquids are all on offer. IV drips are mostly an in-clinic service.

A 2022 conference case described one older migraine patient receiving intranasal NAD+ with lidocaine and later sublingual NAD+. With no control and multiple interventions, it cannot establish a nasal spray effect ^[8]. For the route-specific evidence, read NAD+ nasal spray.

AgelessRx also reports a commercial customer survey: 131 prescription-approved nasal-spray customers supplied self-reported check-in responses between April 2022 and October 2025, and the page says 89% reported benefits by the second check-in. This is a provider-reported survey, with no control group or blinded outcome assessment described on the page. Selection, expectations and other care could affect responses; the percentage is not a proven chance of benefit for a new buyer. ^[5]

How often and for how long? No evidence-based schedule exists

No FDA label or trial sets how often or for how long to take NAD+ injections. The heart-failure trial used a single 7-day course ^[16], which says nothing about weekly shots for months. Any schedule you're given comes from the prescriber or the provider's protocol.

That makes it a fair question to ask: what is this schedule based on, and when would we stop? A good prescriber can tell you what they watch for and what would make them change course. Whether the shots work at all is the subject of do NAD+ injections work.

What NAD+ costs from telehealth providers

NAD+ prices vary by route, supply commitment, introductory offer and required fees. The selected offers below have current product-specific source pages. They are examples for comparing payment terms, not a complete market range or a ranking of effectiveness. An injection price is not directly comparable with a nasal offer: neither price nor route establishes clinical benefit.

The monthly price is rarely the whole story: four billing patterns to spot

NAD+ plans are sold in a handful of shapes, and the headline number means something different in each. Knowing which shape you're looking at tells you what to ask before you pay.

• Introductory offers. Compare the first charge with the renewal amount and ask whether the discount requires a longer supply commitment. An offer-specific lower price should not be assumed to apply to every page under the provider’s brand.
• Prepaid commitments. A per-month equivalent may be charged as a larger amount today. Ask for the total commitment and the policy for unused medication or services if you stop before the term ends.
• Medication plus fees. A one-time purchase option and a subscription price are different offers. Other programs may separate membership, laboratory or shipping charges; compare the full first-year expense using the actual quoted terms.
• Refill interval. A 28-day cycle is shorter than a calendar month. Thirteen four-week cycles are a 52-week comparison convention, not a guarantee of the number of charges between two calendar dates. Ask for the actual payment dates and any notice required before renewal.

Some providers leave a gap. Eden's page prints a first-month medication price but not the price for later months, and CoreAge Rx sets the plan at checkout. Neither is a reason to rule them out. Both are reasons to ask for the full cost before the first charge.

How to get NAD+ legally: a prescription filled by a named pharmacy

Compounded NAD+ injections need a prescription. Telehealth providers handle that with an online intake and a clinician review, then a pharmacy ships the vials. Before you join, these questions separate a careful provider from a storefront:

• Which pharmacy compounds it, and is it a state-licensed 503A pharmacy or a 503B outsourcing facility?
• Does the pharmacy test each lot for sterility and potency, and will they say so in writing?
• Are lab tests part of the plan, or optional?
• What does month two cost, and how do you cancel?

Providers that publish this in their own fine print make the job easier. The NAD+ providers by grade list shows how each one scores on the checks, and how we check explains what each check reads.

Terms used on this page

• Coenzyme: a helper molecule that enzymes need to do their work. NAD+ shuttles electrons in energy metabolism.
• 503A compounding: drugs made by a state-licensed pharmacy for an individual patient's prescription.
• Category 1 (interim policy): nominated ingredients FDA is still evaluating; it doesn't plan to act against pharmacies compounding them under set conditions.
• NAD+ precursor: a molecule, such as NMN or NR, that the body converts into NAD+. Usually taken as a pill.